Loading
Life sciences · Phase EARLY_PHASE1 Trial
ClinicalTrials.gov · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase EARLY_PHASE1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07653464). This is a study registration, not published results. Lead sponsor: University of Missouri-Columbia. Recruitment status: NOT_YET_RECRUITING. Phase: EARLY_PHASE1. Study type: INTERVENTIONAL. Enrollment: 64 participants (ESTIMATED). Conditions: Obesity (BMI>30), Insulin Resistance. Interventions: DRUG: human insulin. Primary outcome measures: Amount of muscle sympathetic nerve activity (MSNA) , Change from baseline at minute 30; Amount of cerebral blood flow , Change from baseline at minute 30; Amount of leg blood flow , Change from baseline at minute 30. Brief summary: Determine the impact of obesity with insulin resistance on the neurovascular response to brain insulin stimulation.